Steven G Dubois

List of Publications by Citations

Source: https://exaly.com/author-pdf/1232989/steven-g-dubois-publications-by-citations.pdf

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

82 2,203 26 45 g-index

88 2,825 6.2 4.86 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
82	Clinical features and outcomes in patients with extraskeletal Ewing sarcoma. <i>Cancer</i> , 2011 , 117, 3027-3	2 6.4	140
81	Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. <i>JAMA Oncology</i> , 2016 , 2, 608-615	13.4	128
80	Markers of angiogenesis and clinical features in patients with sarcoma. <i>Cancer</i> , 2007 , 109, 813-9	6.4	115
79	Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3169-76	2.2	106
78	Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 121-133	21.7	93
77	Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children® oncology group study. <i>Clinical Cancer Research</i> , 2011 , 17, 5113-22	12.9	92
76	Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2452-60	2.2	92
75	Increased risk of second malignant neoplasms in adolescents and young adults with cancer. <i>Cancer</i> , 2016 , 122, 116-23	6.4	88
74	Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1368-75	2.2	83
73	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1341-1367	2.2	75
72	The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. <i>Cancer</i> , 2018 , 124, 4241-4247	6.4	75
71	Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children® Oncology Group. <i>Cancer</i> , 2017 , 123, 4224-4235	6.4	73
70	Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Childrenß Oncology Group. <i>Pediatric Blood and Cancer</i> , 2009 , 52, 324-7	3	61
69	Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children® Oncology Group. <i>Pediatric Blood and Cancer</i> , 2016 , 63, 1771-9	3	61
68	An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkz094	4.6	49
67	Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Childrenß Oncology Group. <i>British Journal of Cancer</i> , 2018 , 119, 615-6	2 ^{8.7}	47
66	Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project. <i>Pediatric Blood and Cancer</i> , 2008 , 51, 589-92	3	45

(2002-2016)

65	A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. <i>Clinical Cancer Research</i> , 2016 , 22, 4014-22	12.9	43
64	Identification of Discrete Prognostic Groups in Ewing Sarcoma. <i>Pediatric Blood and Cancer</i> , 2016 , 63, 47	-53	38
63	Dual HDAC and PI3K Inhibition Abrogates NF B - and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. <i>Cancer Research</i> , 2018 , 78, 4007-4021	10.1	36
62	Timing of first-in-child trials of FDA-approved oncology drugs. <i>European Journal of Cancer</i> , 2019 , 112, 49-56	7.5	33
61	Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience. <i>Pediatric Blood and Cancer</i> , 2016 , 63, 1974-82	3	32
60	Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop. <i>Cancer Genetics</i> , 2016 , 209, 182-94	2.3	29
59	Ushering in the next generation of precision trials for pediatric cancer. <i>Science</i> , 2019 , 363, 1175-1181	33.3	27
58	Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Childrenß Oncology Group study. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 1021-7	3.5	27
57	Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome. <i>Radiology</i> , 2016 , 280, 905-15	20.5	26
56	MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Childrenß Oncology Group. <i>Pediatric Blood and Cancer</i> , 2017 , 64, e26545	3	25
55	Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children® Oncology Group (COG). <i>European Journal of Cancer</i> , 2019 , 112, 66-79	7.5	23
54	Ewing Sarcoma-Diagnosis, Treatment, Clinical Challenges and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	23
53	Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. <i>Pediatric Blood and Cancer</i> , 2018 , 65, e27023	3	22
52	Second malignant neoplasms among children, adolescents and young adults with Wilms tumor. <i>Pediatric Blood and Cancer</i> , 2015 , 62, 1259-64	3	21
51	The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1453-1459	9.7	21
50	Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 97, 270-277	4	20
49	Pediatric NUT-midline carcinoma: Therapeutic success employing a sarcoma based multimodal approach. <i>Pediatric Hematology and Oncology</i> , 2017 , 34, 231-237	1.7	20
48	Pediatric acute blastic natural killer cell leukemia. <i>Leukemia and Lymphoma</i> , 2002 , 43, 901-6	1.9	20

47	Clinical Characteristics and Outcomes of Pediatric Patients with Desmoplastic Small Round Cell Tumor. <i>Rare Tumors</i> , 2016 , 8, 6145	1.1	20
46	Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Childrenß Oncology Group. <i>Clinical Cancer Research</i> , 2016 , 22, 3643-50	12.9	18
45	Age dependency of primary tumor sites and metastases in patients with Ewing sarcoma. <i>Pediatric Blood and Cancer</i> , 2018 , 65, e27251	3	18
44	Clinical Impact of Tumor Mutational Burden in Neuroblastoma. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 695-699	9.7	16
43	DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor. <i>Modern Pathology</i> , 2020 , 33, 1910-1921	9.8	16
42	Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma. <i>Pediatric Blood and Cancer</i> , 2012 , 58, 181-4	3	15
41	Conditional Survival and Predictors of Late Death in Patients With Ewing Sarcoma. <i>Pediatric Blood and Cancer</i> , 2016 , 63, 1091-5	3	13
40	Risk stratification by somatic mutation burden in Ewing sarcoma. <i>Cancer</i> , 2019 , 125, 1357-1364	6.4	13
39	Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. <i>Clinical Cancer Research</i> , 2020 , 26, 2297-2307	12.9	12
38	Clinical features and outcomes of infants with Ewing sarcoma under 12 months of age. <i>Pediatric Blood and Cancer</i> , 2015 , 62, 1947-51	3	11
37	A Novel Fusion in Pediatric Medullary Thyroid Carcinoma. <i>Thyroid</i> , 2019 , 29, 1704-1707	6.2	10
36	Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. <i>Oncotarget</i> , 2017 , 8, 23851-23861	3.3	10
35	Comparison of Epidemiology, Clinical Features, and Outcomes of Patients with Reported Ewing Sarcoma and PNET over 40 Years Justifies Current WHO Classification and Treatment Approaches. <i>Sarcoma</i> , 2018 , 2018, 1712964	3.1	10
34	Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Childrenß Oncology Group Report. <i>Journal of Clinical Oncology</i> , 2021 , JCO2100358	2.2	8
33	Assessment of extent of surgical resection of primary high-grade osteosarcoma by treating institutions: A report from the Children® Oncology Group. <i>Journal of Surgical Oncology</i> , 2016 , 113, 351-	4 ^{2.8}	8
32	Extended Sedation With Continuous Midazolam or Dexmedetomidine Infusion for Young Children Receiving 131 I-MIBG Radiopharmaceutical Therapy for Advanced Neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2016 , 63, 471-8	3	7
31	Duality of purpose: Participant and parent understanding of the purpose of genomic tumor profiling research among children and young adults with solid tumors. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	7
30	Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3506-3514	2.2	7

(2020-2020)

29	Sponsorship of oncology clinical trials in the United States according to age of eligibility. <i>Cancer Medicine</i> , 2020 , 9, 4495-4500	4.8	7
28	Winning the RACE: Expanding pediatric cancer drug approvals. <i>Pediatric Blood and Cancer</i> , 2019 , 66, e27	73,05	6
27	Evaluation of polymorphisms in EWSR1 and risk of Ewing sarcoma: a report from the Childhood Cancer Survivor Study. <i>Pediatric Blood and Cancer</i> , 2012 , 59, 52-6	3	6
26	Late recurrence of ewing sarcoma during pregnancy: a report of 2 cases. <i>Journal of Pediatric Hematology/Oncology</i> , 2008 , 30, 716-8	1.2	6
25	The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. <i>Pediatric Blood and Cancer</i> , 2020 , 67, e28559	3	6
24	Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center. <i>Cancer Medicine</i> , 2020 , 9, 6658-6666	4.8	6
23	The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers. <i>Paediatric Drugs</i> , 2020 , 22, 189-197	4.2	4
22	Second malignancies in patients treated for Ewing sarcoma: A systematic review. <i>Pediatric Blood and Cancer</i> , 2019 , 66, e27938	3	4
21	Belzutifan, a Potent HIF2IInhibitor, in the Pacak-Zhuang Syndrome. <i>New England Journal of Medicine</i> , 2021 , 385, 2059-2065	59.2	4
20	The RACE to accelerate drug development for children with cancer. <i>The Lancet Child and Adolescent Health</i> , 2020 , 4, 714-716	14.5	4
19	Physiologically Based Pharmacokinetic Modeling and Simulation of Sunitinib in Pediatrics. <i>AAPS Journal</i> , 2020 , 22, 31	3.7	3
18	Remarkable Activity of Bortezomib Combined with Chemotherapy in a Phase I Study of Relapsed Childhood Acute Lymphoblastic Leukemia (ALL). A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium <i>Blood</i> , 2008 , 112, 1919-1919	2.2	3
17	Stereotactic Body Radiation Therapy for Metastatic and Recurrent Solid Tumors in Children and Young Adults. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 109, 1396-1405	4	3
16	Correlation of Ezrin Expression Pattern and Clinical Outcomes in Ewing Sarcoma. <i>Sarcoma</i> , 2017 , 2017, 8758623	3.1	2
15	Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology. <i>Cancer Medicine</i> , 2021 , 10, 2310	4.8	2
14	NUT Carcinoma Without Upfront Surgical Resection: A Case Report. <i>Journal of Pediatric Hematology/Oncology</i> , 2021 , 43, e707-e710	1.2	1
13	Trends in conditional survival and predictors of late death in neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2020 , 67, e28329	3	1
12	Landscape of phase 1 clinical trials for minors with cancer in the United States. <i>Pediatric Blood and Cancer</i> , 2020 , 67, e28694	3	1

11	Derivation and validation of risk groups in patients with osteosarcoma utilizing regression tree analysis. <i>Pediatric Blood and Cancer</i> , 2021 , 68, e28834	3	1
10	Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2021 , 87, 621-634	3.5	1
9	Neuroblastoma and Histone Demethylation. New England Journal of Medicine, 2018, 379, 1476-1477	59.2	1
8	High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022 , 42, 1-13	7.1	1
7	Evaluation and Outcome of Central Nervous System Involvement in Pediatric Acute Lymphoblastic Leukemia in Dar es Salaam, Tanzania. <i>Pediatric Blood and Cancer</i> , 2016 , 63, 458-64	3	О
6	Patterns of Translocation Testing in Patients Enrolling in a Cooperative Group Trial for Newly Diagnosed Metastatic Ewing Sarcoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2021 , 145, 1564-1	<i>5</i> 68	O
5	Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021 , 46, 343-352	2.7	0
4	Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms. Journal of Clinical Oncology, 2021 , 39, 3822-3828	2.2	O
3	Reply: Is Extended Sedation Necessary for Young Children Receiving High-Dose (131) I-MIBG Therapy?. <i>Pediatric Blood and Cancer</i> , 2016 , 63, 1868	3	
2	Intraoperative radiotherapy and limb-sparing surgery in the treatment of primary, non-metastatic extremity soft tissue sarcoma. <i>Journal of Radiation Oncology</i> , 2015 , 4, 299-307	0.7	
1	Reply to JG. Wang et al <i>Journal of Clinical Oncology</i> , 2022 , JCO2102922	2.2	